Fig. 2: Immunophenotype characterization of patient and PDX iCCA tissues. | Cell Death & Differentiation

Fig. 2: Immunophenotype characterization of patient and PDX iCCA tissues.

From: Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis

Fig. 2

a The immunohistochemical staining shows the same protein expression pattern of specific CCA markers such as cytokeratines and proliferation proteins both in PDX and in patient tissues. b The panel shows the increase of Notch1 immunoreactivity in the tumor tissue of the patient and the PDX, and a slight immunoreactivity in the peritumoral tissue, mainly localized in biliary vessels.

Back to article page